Current Issues and Future Directions in Treatment

Chee-Kin Hui; George K. K. Lau

doi:10.1055/s-2006-939757

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2006; 26(2): 192-197
DOI: 10.1055/s-2006-939757

Current Issues and Future Directions in Treatment

Chee-Kin Hui¹ ^, ² , George K.K. Lau¹ ^, ²

¹Center for the Study of Liver Diseases, The University of Hong Kong, Hong Kong, SAR, China
²Division of Gastroenterology and Hepatology, Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China

Abstract

ABSTRACT

The clinical sequelae of chronic hepatitis B (CHB), such as liver cirrhosis and hepatocellular carcinoma, are determined mainly by the host immune response to the hepatitis B virus-encoded antigens. Disease remission in CHB has been associated with sustained viral suppression < 10⁴ to 10⁵ copies/mL. This can be achieved by either restoring the host immune control on the virus with immunomodulatory therapy, such as conventional or pegylated interferon-alfa therapy, or by continuous suppression of the viral replication by nucleos(t)ide therapy, such as lamivudine, adefovir dipivoxil, or entecavir treatment. Given that not all patients can tolerate or will respond to interferon-alfa-based therapy, maintenance therapy with nucleos(t)ide therapy is the alternative. However, this latter approach can lead to development of viral resistance and long-term safety concerns. Further improvement in CHB therapy is limited by a lack of understanding of the host immune characteristics associated with sustained disease remission.

KEYWORDS

Hepatitis B virus - nucleos(t)ide analogues - immunomodulators - combination therapy - viral resistance

Full Text

References

REFERENCES

1 Kao J H, Chen D S. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002; 2 395-403
2 Lok A S. The maze of treatments for chronic hepatitis B. N Engl J Med. 2005; 352 2743-2746
3 Ganem D, Prince A M. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med. 2004; 350 1118-1129
4 Lau G KK, Piratvisuth T, Luo K X et al.. Peginterferon alfa-2a (40KD) (PEGASYS^®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. N Engl J Med. 2005; 352 2682-2695
5 Marcellin P, Lau G KK, Bonino F et al.. Peginterferon alfa-2a as monotherapy and in combination with lamivudine versus lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351 1206-1217
6 Janssen H L, van Zonneveld M, Senturk H et al.. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365 123-129
7 Chan H L, Leung N W, Hui A Y et al.. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142 240-250
8 Lai C L, Leung N, Teo E K et al.. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129 528-536
9 Lau G KK, Cooksley H, Ribeiro R M et al.. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology. 2004; 38 272A
10 Liaw Y F, Leung N, Guan R et al.. Asian-Pacific Consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005; 25 472-489
11 Reignat S, Webster G J, Brown D et al.. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med. 2002; 195 1089-1101
12 Chen M T, Billaud J N, Sällberg M et al.. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA. 2004; 101 14913-14918
13 Chisari F V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol. 2000; 156 1117-1132
14 Lau G KK, Liang R, Lee C K et al.. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant (BMT) recipients from anti-HBc+/anti-HBs+ BMT donors. J Infect Dis. 1998; 178 1585-1591
15 Lau G KK, Lok A SF, Liang R HS et al.. Clearance of HBsAg after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 1997; 25 1497-1501
16 Ilan Y, Nagler A, Adler R et al.. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology. 1993; 104 1818-1821
17 Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4 499-511
18 Lau G K. Therapy of hepatitis B: immunological issues in viral clearance. AASLD Postgraduate course. 2005
19 Hui C K, Zhang H Y, Lee N P et al.. Upregulation of toll-like receptor 7 is essential for serological clearance of hepatitis B surface antigen in chronic hepatitis B virus infection. Hepatology. 2005; 42(suppl 1) 707A
20 Thompson A J, Locarnini S, Lau G K et al.. Quantitative HBeAg levels and patterns of TLR-2 and TLR-4 expression on CD14+ monocytes during potent antiviral therapy for chronic hepatitis B. Hepatology. 2005; 42(suppl 1) 579A
21 Chen Y C, Sheen I S, Chu C M, Liaw Y F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002; 123 1084-1089
22 de Franchis R, Hadengue A, Lau G et al.. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003; 39(suppl 1) S3-25
23 Lok A S, McMahon B J. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology. 2001; 34 1225-1241
24 Yang H I, Lu S N, Liaw Y F et al.. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002; 347 168-174
25 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1997; 26 1338-1342
26 Niederau C, Heintges T, Lange S et al.. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996; 334 1422-1427
27 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29 971-975
28 Liaw Y F, Sung J JY, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351 1521-1531
29 Perrillo R P, Wright T, Rakela J et al.. A multicentre United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001; 33 424-432
30 Lau G K, Yiu H H, Fong D Y et al.. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125 1742-1749
31 Chang T T, Gish R, De Man R et al.. Entecavir is superior to lamivudine for the treatment of HBeAg (+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naïve patients. Hepatology. 2004; 40(suppl 1) 193A
32 Marcellin P, Chang T T, Lim S G et al.. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348 808-816
33 Boni C, Bertoletti A, Penna A et al.. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998; 102 968-975
34 Boni C, Penna A, Bertoletti A et al.. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 2003; 39 595-605
35 Marinos G, Naoumov N V, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology. 1996; 24 991-995
36 Malacarne F, Webster G J, Reignat S et al.. Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment. J Infect Dis. 2003; 187 679-682
37 Song B C, Suh D J, Lee H C, Chung Y H, Lee Y S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000; 32 803-806
38 Dienstag J L, Cianciara J, Karayalcin S et al.. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003; 37 748-755
39 Chan H L, Hui A Y, Wong V W et al.. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology. 2005; 41 1357-1364
40 Lok A S, Lai C L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125 1714-1722
41 Hadziyannis S J, Tassopoulos N C, Heathcote E J et al.. Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B. N Engl J Med. 2005; 352 2673-2681
42 Fung S K, Andreone P, Han S H et al.. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol. 2005; 43 937-943
43 Gish R G, Chang T T, De Man R et al.. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg+ chronic hepatitis B patients (study ETV-022). Hepatology. 2005; 42(suppl 1) 267A
44 Tenney D J, Levine S M, Rose R E et al.. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004; 48 3498-3507
45 Lai C L, Gane E, Liaw Y F et al.. Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial. Hepatology. 2005; 42(suppl 1) 232A
46 Yoo B C, Kim J H, Lee K S et al.. A 24 week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24-weeks off-treatment in HBeAg + chronic hepatitis B patients. Hepatology. 2005; 42(suppl 1) 270A
47 Sullivan-Bolyai J, Lim S G, Lee K S et al.. Safety, tolerability, antiviral activity and pharmacokinetics of pradefovir mesylate in patients with chronic hepatitis B virus infection: 24 week interim analysis of a phase II study. Hepatology. 2005; 42(suppl 1) 751A
48 Rigopoulou E I, Suri D, Chokshi S et al.. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology. 2005; 42 1028-1036
49 Ludewig B, Ehl S, Karrer U et al.. Dendritic cells efficiently induce protective antiviral immunity. J Virol. 1998; 72 3812-3818
50 Lu W, Arraes L C, Ferreira W T, Andrieu J M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004; 10 1359-1365
51 Peggs K S, Verfuerth S, Pizzey A et al.. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003; 362 1375-1377
52 Chang J J, Wightman F, Bartholomeusz A et al.. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol. 2005; 79 3038-3051
53 Lauer G M, Nguyen T N, Day C L et al.. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol. 2002; 76 2817-2826
54 Sung J JY, Lai J Y, Zeuzem S et al.. A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol. 2003; 38 25

George K.K LauM.D.

University Department of Medicine, Queen Mary Hospital

102 Pokfulam Road, Hong Kong, SAR, China